Literature DB >> 20537300

GJC2 missense mutations cause human lymphedema.

Robert E Ferrell1, Catherine J Baty, Mark A Kimak, Jenny M Karlsson, Elizabeth C Lawrence, Marlise Franke-Snyder, Stephen D Meriney, Eleanor Feingold, David N Finegold.   

Abstract

Lymphedema is the clinical manifestation of defects in lymphatic structure or function. Mutations identified in genes regulating lymphatic development result in inherited lymphedema. No mutations have yet been identified in genes mediating lymphatic function that result in inherited lymphedema. Survey microarray studies comparing lymphatic and blood endothelial cells identified expression of several connexins in lymphatic endothelial cells. Additionally, gap junctions are implicated in maintaining lymphatic flow. By sequencing GJA1, GJA4, and GJC2 in a group of families with dominantly inherited lymphedema, we identified six probands with unique missense mutations in GJC2 (encoding connexin [Cx] 47). Two larger families cosegregate lymphedema and GJC2 mutation (LOD score = 6.5). We hypothesize that missense mutations in GJC2 alter gap junction function and disrupt lymphatic flow. Until now, GJC2 mutations were only thought to cause dysmyelination, with primary expression of Cx47 limited to the central nervous system. The identification of GJC2 mutations as a cause of primary lymphedema raises the possibility of novel gap-junction-modifying agents as potential therapy for some forms of lymphedema. Copyright 2010 The American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20537300      PMCID: PMC3032064          DOI: 10.1016/j.ajhg.2010.04.010

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  29 in total

Review 1.  Peptide inhibitors of intercellular communication.

Authors:  V M Berthoud; E C Beyer; K H Seul
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2000-10       Impact factor: 5.464

2.  Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema.

Authors:  M J Karkkainen; R E Ferrell; E C Lawrence; M A Kimak; K L Levinson; M A McTigue; K Alitalo; D N Finegold
Journal:  Nat Genet       Date:  2000-06       Impact factor: 38.330

Review 3.  Gap junctions.

Authors:  Daniel A Goodenough; David L Paul
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-07       Impact factor: 10.005

4.  Linkage and sequence analysis indicate that CCBE1 is mutated in recessively inherited generalised lymphatic dysplasia.

Authors:  Fiona Connell; Kamini Kalidas; Pia Ostergaard; Glen Brice; Tessa Homfray; Lesley Roberts; David J Bunyan; Sally Mitton; Sahar Mansour; Peter Mortimer; Steve Jeffery
Journal:  Hum Genet       Date:  2009-11-13       Impact factor: 4.132

5.  Maintenance of intercellular coupling by the antiarrhythmic peptide rotigaptide suppresses arrhythmogenic discordant alternans.

Authors:  Anne Louise Kjølbye; Maria Dikshteyn; Benjamin C Eloff; Isabelle Deschênes; David S Rosenbaum
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-11-02       Impact factor: 4.733

6.  HGF and MET mutations in primary and secondary lymphedema.

Authors:  David N Finegold; Vivien Schacht; Mark A Kimak; Elizabeth C Lawrence; Etelka Foeldi; Jenny M Karlsson; Catherine J Baty; Robert E Ferrell
Journal:  Lymphat Res Biol       Date:  2008       Impact factor: 2.589

7.  Mutations in CCBE1 cause generalized lymph vessel dysplasia in humans.

Authors:  Marielle Alders; Benjamin M Hogan; Evisa Gjini; Faranak Salehi; Lihadh Al-Gazali; Eric A Hennekam; Eva E Holmberg; Marcel M A M Mannens; Margot F Mulder; G Johan A Offerhaus; Trine E Prescott; Eelco J Schroor; Joke B G M Verheij; Merlijn Witte; Petra J Zwijnenburg; Mikka Vikkula; Stefan Schulte-Merker; Raoul C Hennekam
Journal:  Nat Genet       Date:  2009-12       Impact factor: 38.330

8.  Connexin 43 regulates epicardial cell polarity and migration in coronary vascular development.

Authors:  David Y Rhee; Xiao-Qing Zhao; Richard J B Francis; Guo Ying Huang; John D Mably; Cecilia W Lo
Journal:  Development       Date:  2009-09       Impact factor: 6.868

Review 9.  Estimating the population burden of lymphedema.

Authors:  Stanley G Rockson; Kahealani K Rivera
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

10.  Novel pharmacophores of connexin43 based on the "RXP" series of Cx43-binding peptides.

Authors:  Vandana Verma; Bjarne Due Larsen; Wanda Coombs; Xianming Lin; Gaelle Spagnol; Paul L Sorgen; Steven M Taffet; Mario Delmar
Journal:  Circ Res       Date:  2009-06-25       Impact factor: 17.367

View more
  56 in total

Review 1.  Lymphatic communication: connexin junction, what's your function?

Authors:  J D Kanady; A M Simon
Journal:  Lymphology       Date:  2011-09       Impact factor: 1.286

2.  Connexin37 and Connexin43 deficiencies in mice disrupt lymphatic valve development and result in lymphatic disorders including lymphedema and chylothorax.

Authors:  John D Kanady; Michael T Dellinger; Stephanie J Munger; Marlys H Witte; Alexander M Simon
Journal:  Dev Biol       Date:  2011-04-16       Impact factor: 3.582

3.  Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature.

Authors:  Jan Kazenwadel; Genevieve A Secker; Yajuan J Liu; Jill A Rosenfeld; Robert S Wildin; Jennifer Cuellar-Rodriguez; Amy P Hsu; Sarah Dyack; Conrad V Fernandez; Chan-Eng Chong; Milena Babic; Peter G Bardy; Akiko Shimamura; Michael Y Zhang; Tom Walsh; Steven M Holland; Dennis D Hickstein; Marshall S Horwitz; Christopher N Hahn; Hamish S Scott; Natasha L Harvey
Journal:  Blood       Date:  2011-12-06       Impact factor: 22.113

Review 4.  The new era of the lymphatic system: no longer secondary to the blood vascular system.

Authors:  Inho Choi; Sunju Lee; Young-Kwon Hong
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

Review 5.  The lymphatic vasculature in disease.

Authors:  Kari Alitalo
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

6.  Evaluation of Clinical Manifestations in Patients with Severe Lymphedema with and without CCBE1 Mutations.

Authors:  M Alders; A Mendola; L Adès; L Al Gazali; C Bellini; B Dallapiccola; P Edery; U Frank; F Hornshuh; S A Huisman; S Jagadeesh; H Kayserili; W T Keng; D Lev; C E Prada; J R Sampson; J Schmidtke; V Shashi; Y van Bever; N Van der Aa; J M Verhagen; J B Verheij; M Vikkula; R C Hennekam
Journal:  Mol Syndromol       Date:  2012-10-02

Review 7.  Connexins and pannexins in the immune system and lymphatic organs.

Authors:  Aaron M Glass; Elizabeth G Snyder; Steven M Taffet
Journal:  Cell Mol Life Sci       Date:  2015-06-23       Impact factor: 9.261

8.  Mechanisms of Connexin-Related Lymphedema.

Authors:  Jorge A Castorena-Gonzalez; Scott D Zawieja; Min Li; R Sathish Srinivasan; Alexander M Simon; Cor de Wit; Roger de la Torre; Luis A Martinez-Lemus; Grant W Hennig; Michael J Davis
Journal:  Circ Res       Date:  2018-09-28       Impact factor: 17.367

9.  Segregated Foxc2, NFATc1 and Connexin expression at normal developing venous valves, and Connexin-specific differences in the valve phenotypes of Cx37, Cx43, and Cx47 knockout mice.

Authors:  Stephanie J Munger; Xin Geng; R Sathish Srinivasan; Marlys H Witte; David L Paul; Alexander M Simon
Journal:  Dev Biol       Date:  2016-03-04       Impact factor: 3.582

Review 10.  Vascular anomalies: from genetics toward models for therapeutic trials.

Authors:  Melanie Uebelhoer; Laurence M Boon; Miikka Vikkula
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.